# Genprex, Inc.: financial statements, quarterly

GNPX · Nasdaq · CIK 1595248 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gnpx.md) · [Financials](/companies/gnpx/financials.md) · [Filings](/companies/gnpx/filings.md) · [Insiders](/companies/gnpx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gnpx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [4,617](/filings/0001437749-24-034697.md) | [3,713 d](/filings/0001437749-25-010311.md) | [3,274](/filings/0001437749-25-016133.md) | [1,667](/filings/0001437749-25-026965.md) | [2,756](/filings/0001437749-25-035191.md) | [2,838 d](/filings/0001437749-26-010346.md) | [2,540](/filings/0001437749-26-016755.md) | [2,499](/filings/0001437749-26-027846.md) | [2,193](/filings/0001437749-25-035191.md) | [2,196 d](/filings/0001437749-26-010346.md) | [2,746](/filings/0001437749-26-016755.md) | [2,683](/filings/0001437749-26-027846.md) |
| Operating income | $k | [(7,786)](/filings/0001437749-24-034697.md) | [(5,968) d](/filings/0001437749-25-010311.md) | [(5,997)](/filings/0001437749-25-016133.md) | [(6,518)](/filings/0001437749-25-026965.md) | [(4,323)](/filings/0001437749-25-035191.md) | [(4,336) d](/filings/0001437749-26-010346.md) | [(3,969)](/filings/0001437749-26-016755.md) | [(4,682)](/filings/0001437749-26-027846.md) | [(3,346)](/filings/0001437749-25-035191.md) | [(3,519) d](/filings/0001437749-26-010346.md) | [(4,494)](/filings/0001437749-26-016755.md) | [(4,484)](/filings/0001437749-26-027846.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(7,748)](/filings/0001437749-24-034697.md) | [(5,929) d](/filings/0001437749-25-010311.md) | [(5,969)](/filings/0001437749-25-035191.md) | [(6,496)](/filings/0001437749-25-035191.md) | [(4,316)](/filings/0001437749-25-035191.md) | [(4,330) d](/filings/0001437749-26-010346.md) | [(3,965)](/filings/0001437749-26-027846.md) | [(4,675)](/filings/0001437749-26-027846.md) | [(3,799)](/filings/0001437749-25-035191.md) | [(3,790) d](/filings/0001437749-26-010346.md) | [(4,462)](/filings/0001437749-26-027846.md) | [(4,447)](/filings/0001437749-26-027846.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(5.36)](/filings/0001437749-24-034697.md) | not reported | [(3.86)](/filings/0001437749-25-016133.md) | [(3.00)](/filings/0001437749-25-026965.md) | [(61.65)](/filings/0001437749-25-035191.md) | not reported | [(12.98)](/filings/0001437749-26-016755.md) | [(185.30)](/filings/0001437749-26-027846.md) | [(5.00)](/filings/0001437749-25-035191.md) | not reported | [(0.64)](/filings/0001437749-26-016755.md) | [(9.40)](/filings/0001437749-26-027846.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.7](/filings/0001437749-23-031830.md) | [6.7](/filings/0001437749-25-010311.md) | [8.2](/filings/0001437749-24-017061.md) | [2.5](/filings/0001437749-24-025893.md) | [1.5](/filings/0001437749-24-034697.md) | [1.6](/filings/0001437749-26-010346.md) | [3.5](/filings/0001437749-25-016133.md) | [1.3](/filings/0001437749-25-026965.md) | [1.1](/filings/0001437749-25-035191.md) | [7.8](/filings/0001437749-26-027846.md) | [18.0](/filings/0001437749-26-016755.md) | [15.2](/filings/0001437749-26-027846.md) |
| Current assets | $m | [12.9](/filings/0001437749-23-031830.md) | [7.5](/filings/0001437749-25-010311.md) | [9.2](/filings/0001437749-24-017061.md) | [4.4](/filings/0001437749-24-025893.md) | [1.9](/filings/0001437749-24-034697.md) | [2.1](/filings/0001437749-26-010346.md) | [4.2](/filings/0001437749-25-016133.md) | [2.1](/filings/0001437749-25-026965.md) | [1.7](/filings/0001437749-25-035191.md) | [8.4](/filings/0001437749-26-027846.md) | [18.8](/filings/0001437749-26-016755.md) | [15.8](/filings/0001437749-26-027846.md) |
| Total assets | $m | [16.6](/filings/0001437749-23-031830.md) | [10.7](/filings/0001437749-25-010311.md) | [12.6](/filings/0001437749-24-017061.md) | [6.6](/filings/0001437749-24-025893.md) | [3.9](/filings/0001437749-24-034697.md) | [4.1](/filings/0001437749-26-010346.md) | [6.0](/filings/0001437749-25-016133.md) | [3.8](/filings/0001437749-25-026965.md) | [3.6](/filings/0001437749-25-035191.md) | [10.2](/filings/0001437749-26-027846.md) | [20.3](/filings/0001437749-26-016755.md) | [17.1](/filings/0001437749-26-027846.md) |
| Current liabilities | $m | [4.3](/filings/0001437749-23-031830.md) | [3.3](/filings/0001437749-25-010311.md) | [3.8](/filings/0001437749-24-017061.md) | [2.3](/filings/0001437749-24-025893.md) | [2.2](/filings/0001437749-24-034697.md) | [2.5](/filings/0001437749-26-010346.md) | [2.1](/filings/0001437749-25-016133.md) | [2.4](/filings/0001437749-25-026965.md) | [2.6](/filings/0001437749-25-035191.md) | [2.2](/filings/0001437749-26-027846.md) | [3.4](/filings/0001437749-26-016755.md) | [2.3](/filings/0001437749-26-027846.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [2.5](/filings/0001437749-26-010346.md) | not reported | not reported | [2.8](/filings/0001437749-25-035191.md) | [2.2](/filings/0001437749-26-027846.md) | [3.4](/filings/0001437749-26-016755.md) | [2.3](/filings/0001437749-26-027846.md) |
| Shareholders' equity | $m | [12.3](/filings/0001437749-24-034697.md) | [7.4](/filings/0001437749-26-010346.md) | [8.8](/filings/0001437749-25-035191.md) | [4.3](/filings/0001437749-25-035191.md) | [1.7](/filings/0001437749-25-035191.md) | [1.6](/filings/0001437749-26-027846.md) | [3.9](/filings/0001437749-26-027846.md) | [1.4](/filings/0001437749-26-027846.md) | [0.8](/filings/0001437749-25-035191.md) | [8.0](/filings/0001437749-26-027846.md) | [16.9](/filings/0001437749-26-027846.md) | [14.8](/filings/0001437749-26-027846.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,735) d](/filings/0001437749-24-034697.md) | [(4,964) d](/filings/0001437749-25-010311.md) | [(5,298)](/filings/0001437749-25-016133.md) | [(6,569) d](/filings/0001437749-25-026965.md) | [(2,186) d](/filings/0001437749-25-035191.md) | [(3,869) d](/filings/0001437749-26-010346.md) | [(4,161)](/filings/0001437749-26-016755.md) | [(3,864) d](/filings/0001437749-26-027846.md) | [(3,187) d](/filings/0001437749-25-035191.md) | [(4,098) d](/filings/0001437749-26-010346.md) | [(3,138)](/filings/0001437749-26-016755.md) | [(5,139) d](/filings/0001437749-26-027846.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

Shares outstanding: 819,709 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-027846.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.